Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction

Modern Pathology

Volumn 24, Issue 2, 2011, Pages 185-193

  Reisenbichler, Emily S ^a   Balmer, Nicole N ^a   Adams, Amy L ^b   Pfeifer, John D ^c   Hameed, Omar ^a,d,e  

^a University of Alabama at Birmingham   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

breast; cytokeratin 5; cytokeratin 8 18; luminal cytokeratin; p63; papillary carcinoma; papilloma

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; CYTOKERATIN ANTIBODY; PROTEIN P63;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST PAPILLOMA; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

EID: 79551619949     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.197     Document Type: Article

References (29)

1. Tavassoli FA. Pathology of the Breast, Second ed McGraw-Hill Professional: New York, NY, 1999.
2. Mulligan AM, O'Malley FP. Papillary lesions of the breast: a review. Adv Anat Pathol 2007;14:108-119.
3. Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology 2008;52:20-29.
4. Collins LC, Carlo VP, Hwang H, et al. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 2006;30:1002-1007.
5. Jacobs TW, Connolly JL, Schnitt SJ. Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol 2002;26:1095-1110.
6. Elston CW, Sloane JP, Amendoeira I, et al. Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer 2000;36:1769-1772.
7. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 1991;15:209-221.
8. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002;198:458-467.
9. Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 2003;442: 548-554.
10. Moinfar F, Man YG, Lininger RA, et al. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type-benign and malignant intraductal proliferations. Am J Surg Pathol 1999;23:1048-1058.
11. Otterbach F, Bankfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000;37:232-240.
12. Tse GM, Tan PH, Lui PC, et al. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 2007;60: 315-320.
13. Tan PH, Aw MY, Yip G, et al. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol 2005;29:625-632.
14. Douglas-Jones A, Shah V, Morgan J, et al. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63. Histopathology 2005;47:202-208.
15. Ichihara S, Fujimoto T, Hashimoto K, et al. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. Pathol Int 2007;57:126-132.
16. Boecker W. Preneoplasia of the breast : a new conceptual approach to proliferative breast disease. Saunders Elsevier: Munich, 2006.
17. Abdel-Fatah TM, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008;32:513-523.
18. McCarty Jr KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109:716-721.
19. Troxell ML, Masek M, Sibley RK. Immunohistochemical staining of papillary breast lesions. Appl Immunohistochem Mol Morphol 2007;15:145-153.
20. de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, et al. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast. Breast J 2008;14:68-75.
21. Moritani S, Ichihara S, Kushima R, et al. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia. Virchows Arch 2007;450: 539-547.
22. Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol 2005;123:36-44.
23. Saddik M, Lai R. CD44s as a surrogate marker for distinguishing intraductal papilloma from papillary carcinoma of the breast. J Clin Pathol 1999;52:862-864.
24. Tse GM, Tan PH, Ma TK, et al. CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol 2005;58:1185-1188.
25. Denoux Y, Lebeau CH, Michels JJ, et al. Double immunohistochemical labeling technique applied to different types of cytokeratins in epithelial proliferations of the breast. Biotech Histochem 2003;78:23-26.
26. Gurbuz Y, Ozkara SK. Clear cell carcinoma of the breast with solid papillary pattern: a case report with immunohistochemical profile. J Clin Pathol 2003;56: 552-554.
27. Page DL, Salhany KE, Jensen RA, et al. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer 1996;78:258-266.
28. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol 2005;22:88-104.
29. Grin A, O'Malley FP, Mulligan AM. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. Am J Surg Pathol 2009;33: 1615-1623.